Literature DB >> 19815247

Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Sean X Du1, Rebecca J Idiart, Ellaine B Mariano, Helen Chen, Peifeng Jiang, Li Xu, Kristin M Ostrow, Terri Wrin, Pham Phung, James M Binley, Christos J Petropoulos, John A Ballantyne, Robert G Whalen.   

Abstract

The external domains of the HIV-1 envelope glycoprotein (gp120 and the gp41 ectodomain, collectively known as gp140) contain all known viral neutralization epitopes. Various strategies have been used to create soluble trimers of the envelope to mimic the structure of the native viral protein, including mutation of the gp120-gp41 cleavage site, introduction of disulfide bonds, and fusion to heterologous trimerization motifs. We compared the effects on quaternary structure, antigenicity, and immunogenicity of three such motifs: T4 fibritin, a GCN4 variant, and the Escherichia coli aspartate transcarbamoylase catalytic subunit. Fusion of each motif to the C-terminus of a noncleavable JRCSF gp140(-) envelope protein led to enhanced trimerization but had limited effects on the antigenic profile and CD4-binding ability of the trimers. Immunization of rabbits provided no evidence that the trimerized gp140(-) constructs induced significantly improved neutralizing antibodies to several HIV-1 pseudoviruses, compared to gp140 lacking a trimerization motif. However, modest differences in both binding specificity and neutralizing antibody responses were observed among the various immunogens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815247      PMCID: PMC2801758          DOI: 10.1016/j.virol.2009.07.042

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  74 in total

1.  Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

Authors:  R Shibata; T Igarashi; N Haigwood; A Buckler-White; R Ogert; W Ross; R Willey; M W Cho; M A Martin
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

2.  Codon usage limitation in the expression of HIV-1 envelope glycoprotein.

Authors:  J Haas; E C Park; B Seed
Journal:  Curr Biol       Date:  1996-03-01       Impact factor: 10.834

3.  Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.

Authors:  A K Pilgrim; G Pantaleo; O J Cohen; L M Fink; J Y Zhou; J T Zhou; D P Bolognesi; A S Fauci; D C Montefiori
Journal:  J Infect Dis       Date:  1997-10       Impact factor: 5.226

4.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

5.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

7.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

8.  Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection.

Authors:  P Carotenuto; D Looij; L Keldermans; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

9.  Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.

Authors:  P L Earl; C C Broder; D Long; S A Lee; J Peterson; S Chakrabarti; R W Doms; B Moss
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

10.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Authors:  P Roben; J P Moore; M Thali; J Sodroski; C F Barbas; D R Burton
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more
  17 in total

1.  Immunosilencing a highly immunogenic protein trimerization domain.

Authors:  Kwinten Sliepen; Thijs van Montfort; Mark Melchers; Gözde Isik; Rogier W Sanders
Journal:  J Biol Chem       Date:  2015-01-29       Impact factor: 5.157

2.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

3.  A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.

Authors:  Miklos Guttman; Kelly K Lee
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

4.  A directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoprotein.

Authors:  Sean X Du; Li Xu; Wenge Zhang; Susan Tang; Rebecca I Boenig; Helen Chen; Ellaine B Mariano; Michael B Zwick; Paul W H I Parren; Dennis R Burton; Terri Wrin; Christos J Petropoulos; John A Ballantyne; Michael Chambers; Robert G Whalen
Journal:  PLoS One       Date:  2011-06-29       Impact factor: 3.240

Review 5.  Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies.

Authors:  Maria Tagliamonte; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

6.  Basic research in HIV vaccinology is hampered by reductionist thinking.

Authors:  Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2012-07-09       Impact factor: 7.561

7.  A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus.

Authors:  Guillaume B E Stewart-Jones; Paul V Thomas; Man Chen; Aliaksandr Druz; M Gordon Joyce; Wing-Pui Kong; Mallika Sastry; Cinque Soto; Yongping Yang; Baoshan Zhang; Lei Chen; Gwo-Yu Chuang; Ivelin S Georgiev; Jason S McLellan; Sanjay Srivatsan; Tongqing Zhou; Ulrich Baxa; John R Mascola; Barney S Graham; Peter D Kwong
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

8.  Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design.

Authors:  Leopold Kong; Quentin J Sattentau
Journal:  J AIDS Clin Res       Date:  2012-03-22

9.  Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.

Authors:  Kristin M Narayan; Nitish Agrawal; Sean X Du; Janelle E Muranaka; Katherine Bauer; Daniel P Leaman; Pham Phung; Kay Limoli; Helen Chen; Rebecca I Boenig; Terri Wrin; Michael B Zwick; Robert G Whalen
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

10.  Increased functional stability and homogeneity of viral envelope spikes through directed evolution.

Authors:  Daniel P Leaman; Michael B Zwick
Journal:  PLoS Pathog       Date:  2013-02-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.